Overview

Recombinant protein drugs are intimately associated with the impressive success story of the biotech industry during the past 30 years, some of them belonging to the most successful pharmaceutical products. More than 30 different proteins are available for a variety of clinical applications, over 300 proteins are presently being evaluated in clinical trials. In this new volume of the MDT series, historical, technical and clinical aspects of recombinant protein drug discovery and development are presented, covering past, present and future highlights. Leading scientists and co-founders of early biotech companies describe technical breakthroughs and the fascinating story of pioneering discoveries, as well as the long way of translating them into products and business. Therefore, this book represents an exciting documentation of the beginning of a new era in the pharmaceutical industry. In addition, scientists from basic research, clinic and industry actively involved in new developments discuss future applications of recombinant protein therapies. The book should be of value not only to scientists and graduate students in medical, pharmacological and biological research, but also to physicians and researchers in the biotechnological and pharmaceutical industries.

Full Product Details

Author:   P. Buckel
Publisher:   Birkhauser Verlag AG
Imprint:   Birkhauser Verlag AG
Edition:   2001 ed.
Dimensions:   Width: 15.50cm , Height: 1.40cm , Length: 23.50cm
Weight:   1.090kg
ISBN:  

9783764359041

ISBN 10:   3764359048
Pages:   207
Publication Date:   01 August 2001
Audience:   College/higher education ,  Professional and scholarly ,  Undergraduate ,  Postgraduate, Research & Scholarly
Format:   Hardback
Publisher's Status:   Active
Availability:   In Print  
This item will be ordered in for you from one of our suppliers. Upon receipt, we will promptly dispatch it out to you. For in store availability, please contact us.

Table of Contents

Pioneers and business.- Recombinant interferon — the 20th anniversary.- Combining science and business: from recombinant DNA to vaccines against hepatitis B virus.- First generation proteins.- Clotting factors VIII and IX.- Colony-stimulating factors: altering the practice of oncology.- Tissue-type plasminogen activator: helping patients with acute myocardial infarction.- Proteins with new functions: protein engineering.- Designing immunocytokines: genetically engineered fusion proteins for targeted immune therapy.- Further improvement of protein drugs.- Improving protein therapeutics: the evolution of the modern pharmacopoeia.- Principles of gene transfer and foreign protein expression for human gene therapy.- Short biographies.- List of approved “recombinant protein drugs”.

Reviews

Author Information

Tab Content 6

Author Website:  

Countries Available

All regions